Four University Technologies Receive $650,000 from Science Center's QED Program


Dr. Sunday Shoyele, Assistant Professor in the Department of Pharmaceutical Sciences at Jefferson Pharmacy School, whose proposal to develop a product for delivering highly-degradable gene inhibitors to cancer and other cells using antibody-based nanoparticles, has been selected by the Science Center QED Proof-of-Concept program as one of the four awardees from a pool of 68 applicants and nine universities in the Greater Philadelphia region.

This is the first proposal supported by the Jefferson Innovation Pillar to receive the highly competitive QED funding. Dr. Shoyele will receive a total of $200,000 to accelerate his research and better position the promising technology for successful commercial development. The Innovation Pillar is excited for Dr. Shoyele and the Pharmacy School and looks forward to continuing to work closely with them on the further development of this promising and much-needed innovation.

More info per the Science Center press release.

About the QED Program

The QED Program was launched in April 2009. A common participation agreement that defines matching funds, indirect costs, and intellectual property management, has been signed by 21 universities and research institutions in Pennsylvania, New Jersey, and Delaware: The Children's Hospital of Philadelphia, Delaware State University, Drexel University, Fox Chase Cancer Center, Harrisburg University of Science and Technology, Lankenau Institute for Medical Research, Lehigh University, Monell Chemical Senses Center, New Jersey Institute of Technology, The Pennsylvania State University, Philadelphia College of Osteopathic Medicine, Philadelphia University, Rowan University, Rutgers University, Temple University, Thomas Jefferson University, University of Delaware, University of Pennsylvania, University of the Sciences in Philadelphia, Widener University, and The Wistar Institute.